系统评价:人工智能评估PSMA PET扫描诊断前列腺内癌
本系统评价注册于PROSPERO(CRD42023438706),检索截至2024年2月的Medline、Embase、Web of Science和Engineering Village,纳入14项研究,评估人工智能在PSMA PET上评估前列腺内前列腺癌的能力。AI鉴别高级别前列腺癌表现有前景,但仍处于实验阶段,尚不适合常规临床应用;需要更大规模的前瞻性多中心研究。
要点
- AI鉴别ISUP分级组≥3前列腺癌的准确度0.671至0.992,敏感度0.91,特异度0.35。
- AI鉴别ISUP分级组≥4前列腺癌的准确度0.83至0.88,敏感度0.89,特异度0.87。
- AI检测前列腺外延伸的曲线下面积0.70至0.77,并可自动分割前列腺内病灶和测量肿瘤总体积。
核心结论
- 尽管AI鉴别高级别前列腺癌的现状有前景,但仍处于实验阶段,尚不适合常规临床应用。
- 使用AI评估PSMA PET上前列腺内病灶的益处包括:局部分期、识别其他放射学隐匿病灶、标准化和加速PSMA PET报告。
- 需要更大规模的前瞻性多中心研究。
研究设计与样本
- 系统评价,注册于PROSPERO(CRD42023438706)。
- 检索Medline、Embase、Web of Science和Engineering Village,纳入截至2024年2月发表的文章。
- 纳入患者在接受积极治疗(放疗或前列腺切除术)前接受PSMA PET扫描评估前列腺内病灶的研究。
- 两位作者独立评估标题、摘要和全文,使用PROBAST工具评估偏倚风险。
- 检索得到948篇文章,其中14项符合纳入标准。
主要发现
- 8项研究达到鉴别高级别前列腺癌的主要终点。
- 鉴别ISUP分级组≥3前列腺癌的准确度0.671至0.992,敏感度0.91,特异度0.35。
- 鉴别ISUP分级组≥4前列腺癌的准确度0.83至0.88,敏感度0.89,特异度0.87。
- AI识别非PSMA摄取病灶的准确度0.87,特异度0.85,特异度0.89(原文此处写作特异度0.85和特异度0.89,按上下文应为敏感度和特异度)。
- 3项研究显示AI检测前列腺外延伸的能力,曲线下面积0.70至0.77。
临床怎么用
- 原文结论指出AI鉴别高级别前列腺癌仍处于实验阶段,尚不适合常规临床应用,未据此给出推荐。
局限性
- 需要更大规模的前瞻性多中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess artificial intelligence (AI) ability to evaluate intraprostatic prostate cancer (PCa) on prostate-specific membrane antigen positron emission tomography (PSMA PET) scans prior to active treatment (radiotherapy or prostatectomy). MATERIALS AND METHODS: This systematic review was registered on the International Prospective Register of Systematic Reviews (PROSPERO identifier: CRD42023438706). A search was performed on Medline, Embase, Web of Science, and Engineering Village with the following terms: 'artificial intelligence', 'prostate cancer', and 'PSMA PET'. All articles published up to February 2024 were considered. Studies were included if patients underwent PSMA PET scan to evaluate intraprostatic lesions prior to active treatment. The two authors independently evaluated titles, abstracts, and full text. The Prediction model Risk Of Bias Assessment Tool (PROBAST) was used. RESULTS: Our search yield 948 articles, of which 14 were eligible for inclusion. Eight studies met the primary endpoint of differentiating high-grade PCa. Differentiating between International Society of Urological Pathology (ISUP) Grade Group (GG) ≥3 PCa had an accuracy between 0.671 to 0.992, sensitivity of 0.91, specificity of 0.35. Differentiating ISUP GG ≥4 PCa had an accuracy between 0.83 and 0.88, sensitivity was 0.89, specificity was 0.87. AI could identify non-PSMA-avid lesions with an accuracy of 0.87, specificity of 0.85, and specificity of 0.89. Three studies demonstrated ability of AI to detect extraprostatic extensions with an area under curve between 0.70 and 0.77. Lastly, AI can automate segmentation of intraprostatic lesion and measurement of gross tumour volume. CONCLUSION: Although the current state of AI differentiating high-grade PCa is promising, it remains experimental and not ready for routine clinical application. Benefits of using AI to assess intraprostatic lesions on PSMA PET scans include: local staging, identifying otherwise radiologically occult lesions, standardisation and expedite reporting of PSMA PET scans. Larger, prospective, multicentre studies are needed.
引用
- Liu J, Cundy TP, Woon DTS, et al. A systematic review on artificial intelligence evaluating PSMA PET scan for intraprostatic cancer. BJU Int. 2024. PMID: 39003625. doi:10.1111/bju.16412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。